Cerebrolysin is a recurring topic in our peptide coverage. This hub collects every article tagged Cerebrolysin, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical, evidence-graded ranking of the peptides marketed for neuroprotection — Cerebrolysin, Semax, ARA-290, SS-31/elamipretide and P021 — separating a modest, mixed human signal from elegant but preclinical-only mechanism.
A clinical, evidence-graded ranking of the peptides studied for nerve injury and neuropathy — ARA-290, Cerebrolysin, BPC-157 and Cortagen — separating genuine human RCT data from animal-only signal.
A clinical, evidence-graded ranking of the peptides marketed for memory — Cerebrolysin, Semax, Noopept, Dihexa and P021 — separating the disputed human RCT signal from preclinical mechanism, a retracted-data scandal, and pure marketing.
A clinical, evidence-graded look at the peptides marketed for focus and "brain fog" — Semax, Selank, Cerebrolysin and the N-Acetyl modified analogs — separating the small human attention signal from preclinical mechanism and pure marketing.
A clinical, evidence-first look at the peptides marketed for ME/CFS — thymosin alpha-1, elamipretide (SS-31), MOTS-c and cerebrolysin. The honest headline: no peptide has a completed CFS efficacy trial.
A clinical, evidence-graded look at the three peptides marketed for depression — Cerebrolysin, Selank and Semax — separating secondary-endpoint human data and preclinical antidepressant signals from marketing hype.
A clinical monograph on Cerebrolysin — the porcine-brain-derived neuropeptide mixture studied for stroke, TBI and dementia. A large but deeply contested human-RCT base, no FDA approval, and an unresolved safety signal.
Cerebrolysin is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Cerebrolysin, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.